Chromosome 22q11.2 deletion syndrome: Difference between revisions
imported>Daniel Mietchen m (word order) |
mNo edit summary |
||
| (3 intermediate revisions by one other user not shown) | |||
| Line 2: | Line 2: | ||
{{DirectRef}} | {{DirectRef}} | ||
'''Chromosome 22q11.2 deletion syndrome''' is a clinical condition due to [[microdeletion]]s in the [[chromosome band|11.2 region]] on [[human chromosome 22]]. The term is also often used interchangeably with [[velocardiofacial syndrome]] or [[DiGeorge syndrome]], although the overlap between the conditions is not complete ([[CZ:Ref:Kobrynski 2007 Velocardiofacial syndrome, DiGeorge syndrome: the chromosome 22q11.2 deletion syndromes|Kobrynski and Sullivan, 2007]]). It was first diagnosed in 1968 by [[Angelo DiGeorge]] as an [[immunological]] syndrome but has since been found to be associated with a wide [[phenotype|phenotypic]] spectrum which also includes [[cardiovascular]], [[craniofacial]] and [[brain morphometric]] abnormalities as well as [[cognitive impairment]]s. | '''Chromosome 22q11.2 deletion syndrome''' (abbrev. 22q11.2DS) is a clinical condition due to [[microdeletion]]s in the [[chromosome band|11.2 region]] on [[human chromosome 22]]. The term is also often used interchangeably with [[velocardiofacial syndrome]] or [[DiGeorge syndrome]], although the overlap between the conditions is not complete ([[CZ:Ref:Kobrynski 2007 Velocardiofacial syndrome, DiGeorge syndrome: the chromosome 22q11.2 deletion syndromes|Kobrynski and Sullivan, 2007]]). It afflicts about one in 5000 newborn children and can be diagnosed with a [[genetic test]]. It was first diagnosed in 1968 by [[Angelo DiGeorge]] as an [[immunological]] syndrome but has since been found to be associated with a wide [[phenotype|phenotypic]] spectrum which also includes [[cardiovascular]], [[craniofacial]] and [[brain morphometric]] abnormalities as well as [[cognitive impairment]]s. For instance, more than half of the 22q11.2DS patients are affected by [[congenital heart disease]] ([[CZ:Ref:McDonald-McGinn 1999 The Philadelphia story: the 22q11.2 deletion: report on 250 patients|McDonald-McGinn et al., 1999]]), and 22q11.2DS is also frequently associated with [[polymicrogyria]] ([[CZ:Ref:Robin 2006 Polymicrogyria and deletion 22q11.2 syndrome: window to the etiology of a common cortical malformation|Robin et al., 2006]]), possibly due to [[perinatal]] [[cardiovascular]] effects ([[CZ:Ref:Barkovich 1995 Correlation of prenatal events with the development of polymicrogyria|Barkovich et al., 1995]]).[[Category:Suggestion Bot Tag]] | ||
Latest revision as of 16:01, 28 July 2024
This article uses direct referencing.
Chromosome 22q11.2 deletion syndrome (abbrev. 22q11.2DS) is a clinical condition due to microdeletions in the 11.2 region on human chromosome 22. The term is also often used interchangeably with velocardiofacial syndrome or DiGeorge syndrome, although the overlap between the conditions is not complete (Kobrynski and Sullivan, 2007). It afflicts about one in 5000 newborn children and can be diagnosed with a genetic test. It was first diagnosed in 1968 by Angelo DiGeorge as an immunological syndrome but has since been found to be associated with a wide phenotypic spectrum which also includes cardiovascular, craniofacial and brain morphometric abnormalities as well as cognitive impairments. For instance, more than half of the 22q11.2DS patients are affected by congenital heart disease (McDonald-McGinn et al., 1999), and 22q11.2DS is also frequently associated with polymicrogyria (Robin et al., 2006), possibly due to perinatal cardiovascular effects (Barkovich et al., 1995).